• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

cell therapy

Reorganization team change restructure
Biotech

Industry disappointed as FDA reportedly puts Verdun on leave

The FDA has reportedly put the director of its cell and gene therapy office on administrative leave and escorted her out of the agency.
Nick Paul Taylor Jun 20, 2025 1:53am
Businessman about to be crushed by falling dominos
Favicon Fierce Pharma

BioNTech to wind down cell therapy manufacturing in Maryland

Jun 18, 2025 10:23am
pendulum silver metallic spheres on coloured background with drop shadow

As investors pivot from cell therapy, Immatics keeps the faith

Jun 6, 2025 3:50am
embryonic stem cells

ASCO: Immatics cell therapy sees 56% ORR in advanced melanoma

May 31, 2025 8:00am
Terminated contract

NIH nixes financing for Pluri's radiation exposure cell therapy

Apr 18, 2025 9:10am
too many options

Adaptimmune questions own longevity, axes preclinical funding

Mar 20, 2025 2:04pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings